Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

🤖 Plain-English Summary

BACKGROUND: Large trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with heart failure or chronic kidney disease, or with type 2 diabetes and high risk of atherosclerotic cardiovascular disease. INTERPRETATION: In addition to the established cardiovascular benefits of SGLT2 inhibitors, the randomised data support their use for modifying risk of kidney disease progression and acute kidney injury, not...

🔑 Key Findings

• None of the trials recruiting patients with and without diabetes were designed to assess outcomes separately in patients without diabetes.
• METHODS: We did a systematic review and meta-analysis of SGLT2 inhibitor trials.
• We searched the MEDLINE and Embase databases for trials published from database inception to Sept 5, 2022.

🔗 Related Resources